Cedar Crosse Research is conducting a groundbreaking study aimed at revolutionizing the management of type 2 diabetes. The primary goal is to evaluate the effectiveness of a new weekly medication, IcoSema – a combination of insulin icodec and semaglutide – in controlling blood sugar levels. This will be benchmarked against the daily administration of insulin glargine.
Key Objectives:
- To assess the long-term blood sugar level management using IcoSema.
- To compare the efficacy of IcoSema with the daily insulin glargine.
- To understand the potential benefits and risks of weekly diabetes medication treatment.
Methodology
The study involves a commitment of 23 site visits spread over 47 weeks. Participants will be closely monitored and regularly assessed to ensure accurate and comprehensive results.
Participation Details
Those interested in taking a step forward in the battle against type 2 diabetes through this study are encouraged to reach out. Your involvement could be influential in transforming diabetes treatment and improving quality of life for many.
Participant Eligibility:
- Must have type 2 diabetes.
- Currently taking 1-3 oral diabetes medications for at least the past 90 days.
- Have a Body Mass Index (BMI) of less than 40.
- Must not have taken insulin therapy previously (insulin naive).